These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9286660)

  • 1. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer.
    Morita T; Kikuchi T; Hashimoto S; Kobayashi Y; Tokue A
    Eur Urol; 1997; 32(2):237-44. PubMed ID: 9286660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
    Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
    J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer.
    Senga Y; Kimura G; Hattori T; Yoshida K
    Urology; 1996 Nov; 48(5):703-10. PubMed ID: 8911513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYFRA 21-1 serum analysis in patients with esophageal cancer.
    Brockmann JG; St Nottberg H; Glodny B; Heinecke A; Senninger NJ
    Clin Cancer Res; 2000 Nov; 6(11):4249-52. PubMed ID: 11106239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
    Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T
    Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma.
    Uenishi T; Yamazaki O; Yamamoto T; Hirohashi K; Tanaka H; Tanaka S; Hai S; Ono K; Kubo S
    J Hepatobiliary Pancreat Surg; 2006; 13(3):239-44. PubMed ID: 16708302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
    Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
    Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
    Pavićević R; Milicić J; Bubanović G; Supe S
    Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder.
    Satyam A; Singh P; Sharma M; Seth A; Sharma A
    Biomarkers; 2011 Aug; 16(5):413-21. PubMed ID: 21777169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer.
    Stieber P; Schmeller N; Schambeck C; Hofmann K; Reiter W; Hasholzner U; Fateh-Moghadam A
    Anticancer Res; 1996; 16(6B):3793-8. PubMed ID: 9042259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.
    Pariente JL; Bordenave L; Jacob F; Gobinet A; Leger F; Ferriere JM; Le Guillou M
    J Urol; 2000 Apr; 163(4):1116-9. PubMed ID: 10737478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
    Hirashima T; Takada M; Komiya T; Nitta T; Masashi K; Masuda N; Matui K; Kikui M; Yasumitsu T; Kawase I
    Anticancer Res; 1998; 18(6B):4713-6. PubMed ID: 9891546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
    González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A
    Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.